Fly News Breaks for April 13, 2015
Apr 13, 2015 | 07:35 EDT
Stifel anticipates results from the CUPID2 trial of Celladon's Mydicar in the next two to four weeks, and the firm is "cautiously optimistic" about the trial's outcome. The firm says that the stock could rise significantly if the results are positive. It believes that Mydicar could address a multi-billion dollar commercial opportunity. Stifel keeps a $28 price target and Buy rating on the shares.
News For CLDN From the Last 2 Days
There are no results for your query CLDN